Comic Book Artist J.G. Jones on His Project Illustrating Patients with Rare Blood Cancers

J.G. Jones is a renowned comic book artist, illustrating covers of beloved superhero novels like Batman and Robin, Doc Savage, and Frankenstein. He has probably worked for all of the…

Continue Reading Comic Book Artist J.G. Jones on His Project Illustrating Patients with Rare Blood Cancers

Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day

Myeloproliferative neoplasm (MPN) International Awareness Day is on September 10th. This year, there will be a live streaming event to help bring awareness to this condition, instead of an in-person…

Continue Reading Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day
Combination Treatment for Myelofibrosis Shows Potential in Early Trial
source: pixabay.com

Combination Treatment for Myelofibrosis Shows Potential in Early Trial

According to a story from Targeted Oncology, findings from a recent phase 1 trial have discovered a new potential treatment for myelofibrosis. The study combined two different drugs: panobinostat (marketed…

Continue Reading Combination Treatment for Myelofibrosis Shows Potential in Early Trial
Medical College of Wisconsin Creates ER Alternative for Treating Myeloproliferative Neoplasms and Other Cancers
source: pixabay.com

Medical College of Wisconsin Creates ER Alternative for Treating Myeloproliferative Neoplasms and Other Cancers

Cancer patients often face adverse effects from their treatment. These effects typically need to be addressed by a doctor, whether they're nausea, rashes, or anything else. The issue is that…

Continue Reading Medical College of Wisconsin Creates ER Alternative for Treating Myeloproliferative Neoplasms and Other Cancers

Is This Experimental Drug the Next New Treatment for Myelofibrosis?

According to a story from Targeted Oncology, recent data suggests that the experimental therapy IMG-7289 could be a useful treatment for patients with myelofibrosis, a rare type of cancer that…

Continue Reading Is This Experimental Drug the Next New Treatment for Myelofibrosis?

Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis

Hereditary Hemochromatosis Hereditary hemochromatosis (HH) is a rare disease caused by hepcidin deficiency or hepcidin insensitivity. Hepcidin naturally regulates iron absorption/distribution in the body. Without hepcidin, HH patients suffer from…

Continue Reading Extremely Positive Results Announced from Interim Analysis of Phase 2 Clinical Trial for Hemochromatosis
Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
qimono / Pixabay

Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study

According to a publication from Oncology Nurse Advisor, a study of 109 patients with myeloproliferative neoplasms (certain types of blood cancers) found that mortality rates for younger patients were similar…

Continue Reading Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
Olympian Scott Hamilton Honors Group of People Who Serve Rare Blood Cancer Community
Source: Pixabay.com

Olympian Scott Hamilton Honors Group of People Who Serve Rare Blood Cancer Community

Olympian skater Scott Hamilton was the keynote speaker at the CURE media group's sixth annual myeloproliferative neoplasm (MPN) Heroes celebration, honoring nine individuals who have also dedicated themselves to improving the lives…

Continue Reading Olympian Scott Hamilton Honors Group of People Who Serve Rare Blood Cancer Community
Study Shows the Most Effective Treatments for Polycythemia Vera are Under-prescribed
source: pixabay.com

Study Shows the Most Effective Treatments for Polycythemia Vera are Under-prescribed

Polycythemia Vera or PV, is a rare blood cancer. It's caused by a mutation which results in the overproduction of red blood cells. Too many blood cells significantly increases your…

Continue Reading Study Shows the Most Effective Treatments for Polycythemia Vera are Under-prescribed
Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
stevepb / Pixabay

Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released

The drug Jakavi (ruxolitinib) is being investigated as a possible treatment for polycythemia vera (PV) and myelofibrosis. Results from studies into this were presented by Novartis at the 23rd Congress of…

Continue Reading Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
Close Menu